Feb-25-21 Downgrade
William Blair
Outperform → Mkt Perform
Jan-20-21 Downgrade
Piper Sandler
Overweight → Neutral
$75 → $50
Dec-15-20 Resumed
H.C. Wainwright
Buy
$75
Dec-03-20 Initiated
RBC Capital Mkts
Outperform
$75
Nov-06-20 Downgrade
Raymond James
Outperform → Mkt Perform
Oct-06-20 Initiated
Evercore ISI
Outperform
$102
Aug-25-20 Initiated
Raymond James
Outperform
$115
Jul-20-20 Initiated
ROTH Capital
Buy
$129
Jul-13-20 Initiated
BofA Securities
Buy
$92
Jul-01-20 Upgrade
Goldman
Neutral → Buy
$91 → $103
Apr-28-20 Initiated
Stifel
Buy
$112
Jan-31-20 Downgrade
SunTrust
Buy → Hold
$110 → $75
Nov-25-19 Resumed
Cantor Fitzgerald
Overweight
$110 → $98
Nov-06-19 Initiated
Canaccord Genuity
Hold
$50
May-29-19 Resumed
Goldman
Neutral
Dec-03-18 Reiterated
H.C. Wainwright
Buy
$125 → $150
Aug-06-18 Initiated
Piper Jaffray
Overweight
$80
Jun-27-18 Reiterated
H.C. Wainwright
Buy
$73 → $125
Jun-27-18 Reiterated
Cantor Fitzgerald
Overweight
$69 → $96
May-08-18 Reiterated
SunTrust
Buy
$80 → $77
Feb-25-21 04:01AM
Feb-24-21 04:44PM
04:05PM
02:30PM
Feb-23-21 10:28AM
Feb-19-21 08:00AM
Feb-17-21 08:00AM
Feb-08-21 01:02AM
Feb-05-21 08:00AM
Feb-04-21 08:00AM
Jan-28-21 10:12AM
Jan-27-21 07:00AM
Jan-07-21 08:00AM
Jan-06-21 08:13AM
Jan-05-21 08:00AM
Dec-25-20 01:54AM
Dec-16-20 10:25AM
Dec-15-20 08:13AM
08:00AM
Dec-07-20 08:00AM
Dec-06-20 10:00AM
10:00AM
Dec-05-20 11:32AM
Dec-03-20 09:56AM
Dec-02-20 07:00AM
Nov-25-20 08:00AM
Nov-13-20 08:45AM
08:00AM
Nov-10-20 06:04AM
Nov-09-20 08:00AM
Nov-07-20 09:38AM
Nov-06-20 12:13PM
10:54AM
Nov-05-20 06:25PM
04:05PM
02:30PM
Nov-04-20 03:11PM
Nov-02-20 08:11AM
Oct-29-20 08:00AM
Oct-26-20 06:00AM
Oct-12-20 08:00AM
Oct-05-20 08:00AM
Sep-18-20 11:31AM
Sep-17-20 09:48AM
Sep-15-20 12:43AM
Sep-09-20 08:00AM
Sep-08-20 04:05PM
Sep-04-20 11:31AM
08:00AM
Sep-03-20 08:00AM
Aug-26-20 10:44PM
Aug-25-20 11:39AM
09:35AM
Aug-07-20 08:00AM
Aug-05-20 05:35PM
04:01PM
Aug-03-20 12:54PM
Jul-30-20 08:00AM
Jul-29-20 08:00AM
Jul-25-20 09:10AM
Jul-17-20 12:45PM
Jul-08-20 08:00AM
Jun-25-20 01:00PM
08:59AM
Jun-24-20 08:30AM
Jun-19-20 01:18AM
Jun-18-20 04:05PM
09:48AM
Jun-12-20 06:37PM Investor's Business Daily
Jun-09-20 10:13AM
02:08AM
Jun-08-20 04:05PM
Jun-05-20 11:31AM
Jun-03-20 08:00AM
Jun-02-20 10:21PM Thomson Reuters StreetEvents
08:00AM
May-29-20 06:45AM
May-24-20 12:25PM
May-15-20 10:58AM
May-14-20 09:05AM
May-07-20 08:00AM
05:48AM
May-06-20 05:35PM
04:05PM
May-05-20 08:45AM
May-04-20 09:10AM
08:55AM
Apr-29-20 08:00AM
07:00AM
Apr-05-20 09:02PM
Apr-03-20 08:00AM
Apr-02-20 01:00PM
Mar-27-20 11:31AM
Mar-18-20 05:21PM Thomson Reuters StreetEvents
06:40AM
Mar-17-20 08:00AM
Mar-04-20 02:13PM
08:00AM
Feb-29-20 08:25AM
Feb-27-20 09:10AM
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. The company has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Fink Eric Chief Human Resources Officer Oct 05 Sale 60.00 4,532 271,920 0 Oct 07 05:12 PM PIERCE GLENN Director Sep 10 Option Exercise 15.03 15,000 225,450 19,800 Sep 14 06:12 PM CATHERS BRIAN EDWIN Chief Scientific Officer Aug 20 Sale 63.77 2,200 140,294 5,244 Aug 24 05:14 PM Fink Eric Chief Human Resources Officer Aug 05 Sale 69.62 2,454 170,851 0 Aug 07 04:09 PM Farrow Jeffrey S Chief Financial Officer Jul 13 Sale 75.00 15,208 1,140,600 3,048 Jul 15 05:11 PM Svoronos Dawn Director Jun 19 Sale 63.94 2,544 162,663 2,256 Jun 19 09:31 PM Farrow Jeffrey S Chief Financial Officer Jun 09 Sale 67.00 15,208 1,018,936 18,256 Jun 11 04:06 PM Calhoun Lesley Ann See Remarks May 26 Option Exercise 29.75 2,700 80,325 2,854 May 28 04:05 PM Calhoun Lesley Ann See Remarks May 26 Sale 70.10 2,700 189,270 154 May 28 04:05 PM Calhoun Lesley Ann See Remarks May 18 Option Exercise 22.00 23,330 513,260 23,484 May 20 04:07 PM Calhoun Lesley Ann See Remarks May 18 Sale 74.67 23,330 1,742,051 154 May 20 04:07 PM PERRY MARK L Director May 12 Option Exercise 22.04 53,600 1,181,500 80,028 May 13 06:07 PM Calhoun Lesley Ann See Remarks May 12 Sale 78.38 2,992 234,512 154 May 13 06:08 PM PERRY MARK L Director May 12 Sale 78.10 53,600 4,186,061 26,428 May 13 06:07 PM Calhoun Lesley Ann See Remarks May 11 Sale 77.05 381 29,356 3,146 May 13 06:08 PM LOVE TED W See Remarks Apr 28 Sale 80.00 40,000 3,200,160 1,034,633 Apr 29 04:17 PM LOVE TED W See Remarks Apr 27 Sale 80.87 2,817 227,814 1,074,633 Apr 29 04:17 PM SUVARI TRICIA BORGA Chief Legal Officer Apr 20 Sale 75.00 4,080 306,000 7,441 Apr 22 04:05 PM Brown Willie L. Jr. Director Mar 13 Buy 52.37 10,000 523,700 31,428 Mar 17 05:53 PM Lehrer-Graiwer Joshua Chief Medical Officer Mar 09 Option Exercise 19.89 938 18,657 3,533 Mar 09 07:37 PM Lehrer-Graiwer Joshua Chief Medical Officer Mar 09 Sale 59.90 938 56,186 2,595 Mar 09 07:37 PM Lehrer-Graiwer Joshua Chief Medical Officer Mar 05 Sale 65.30 1,138 74,311 2,595 Mar 09 07:37 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite